The world's political record
Records whose title is actually about this topic. Use a country filter if the list is still too broad.
601 records in US in 2017
United States · United States Congress · 18 May 2017
Special Diabetes Program for Indians Reauthorization Act of 2017 This bill amends the Public Health Service Act to extend through FY2024 funding for the Special Diabetes Program for Indians.
United States · United States Congress · 18 May 2017
Teacher Health and Wellness Act This bill directs the National Institutes of Health to carry out a five-year study on reducing teacher stress and increasing teacher retention and well-being by implementing and analyzing the results of any of several types of innovative approaches that include: workplace wellness programs; social emotional learning programs; teacher stress management programs; mentoring and induction programs during the school year and teacher pre-service; organizational interventions such as principal training programs; teacher residency programs; complementary health approaches, such as mindfulness meditation; and school reorganization.
United States · United States Congress · 18 May 2017
Lifespan Respite Care Reauthorization Act of 2017 This bill amends the Public Health Service Act to extend lifespan respite care programs (services for family caregivers of children and adults with special needs) through FY2022. Each state agency awarded a grant or cooperative agreement for lifespan respite care must collect, maintain, and report to the Department of Health and Human Services data and records to enable monitoring and evaluation of the lifespan programs and activities.
United States · United States Congress · 18 May 2017
Expresses support for the designation of Stroke Awareness Month. Encourages: (1) support for the efforts, programs, services, and advocacy of organizations that work to enhance public awareness of stroke; and (2) continued coordination and cooperation between government, researchers, families, and the public to improve treatments and prognoses for individuals who suffer strokes.
United States · United States Congress · 18 May 2017
Reaffirms the critical role of frontline health workers in achieving core global health goals. Commends U.S. progress in helping to build local capacity and save lives in the world's most vulnerable communities by training and supporting such workers. Urges greater global attention and support for such workers to ensure their protection and their ability to respond effectively during humanitarian and public health crises and to safeguard the health of the world's most vulnerable populations. Calls on all relevant federal agencies to develop a health workforce strengthening action plan with concrete targets for increasing equitable access to qualified health workers in low- and middle-income countries to support the Global Strategy on Human Resources for Health: Workforce 2030 and recommendations of the High-Level Commission on Health Employment and Economic Growth.
United States · United States Congress · 18 May 2017
Lifespan Respite Care Reauthorization Act of 2017 This bill amends the Public Health Service Act to extend lifespan respite care programs (services for family caregivers of children and adults with special needs) through FY2022. Each state agency awarded a grant or cooperative agreement for lifespan respite care must collect, maintain, and report to the Department of Health and Human Services data and records to enable monitoring and evaluation of the lifespan programs and activities.
United States · United States Congress · 18 May 2017
FDA Regulatory Efficiency Act This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish a third-party quality system assessment program to accredit persons to assess whether a medical device manufacturer's quality system can ensure the safety and effectiveness or substantial equivalence of an approved medical device after certain changes, including changes in manufacturing or changes to enhance device safety. Device manufacturers with quality systems that have been certified by an accredited person are allowed to make changes to a device without submitting to the FDA the premarket notification, 30-day notice, or premarket approval supplement that would otherwise be required. An accredited person who assesses a device manufacturer's quality system must submit a summary of their assessment and, as appropriate, a certification of the quality system to the FDA within 30 days of the assessment. An assessment summary and certification is deemed accepted by the FDA 30 days after submission unless the FDA determines that additional information is needed to support certification, the assessment or certification is unwarranted, or an action other than acceptance of the certification is otherwise justified. Device manufacturers who make changes to devices without submitting a premarket notification must describe the changes in an annual summary submitted to the FDA. Changes made without submitting a 30-day notice or a premarket approval supplement must be described in a periodic report. Certifications accepted by the FDA remain in effect for two years. The FDA must report on this quality system assessment program no later than January 31, 2022. The program is terminated at the end of FY2022.
United States · United States House of Representatives · 17 May 2017
United States · United States Congress · 17 May 2017
Leading Infrastructure for Tomorrow's America Act This bill authorizes appropriations for the nation's infrastructure, including appropriations for: secure broadband internet access, with a prioritization on expanding broadband access in unserved areas; drinking water improvements, such as appropriations for the drinking water state revolving fund and programs for reducing lead in drinking water; the electric power grid, with a focus on grid modernization, security, resiliency, and efficiency; energy efficiency in buildings, including homes and schools; incentives for natural gas distribution companies to improve the public safety and environmental performance of the natural gas distribution system (e.g., pipeline replacements); the deployment of renewable energy systems; the incorporation of clean energy into community development and revitalization efforts; revitalization of brownfield sites (commercial properties that are hindered from reuse or redevelopment due to the presence of a hazardous substance, pollutant, or contaminant); hospital infrastructure, with a prioritization given to projects that include cybersecurity; outpatient health care facilities in the Indian Health Service; and the improvement, renovation, or modernization of the infrastructure at clinical laboratories, teaching health centers, or behavioral health care centers. In addition, the bill reauthorizes funding for: (1) a diesel emissions reduction program for certain diesel vehicles or fleets, (2) ensuring the Strategic Petroleum Reserve is operated and maintained in an environmentally sound manner; and (3) establishing a Southeast Refined Product Reserve to mitigate the impacts of a severe energy supply interruption in the Southeast.
United States · United States Congress · 17 May 2017
Veterans Acquiring Community Care Expect Safe Services Act of 2017 or the Veterans ACCESS Act This bill directs the Department of Veterans Affairs (VA) to deny or revoke eligibility to provide non-VA health care services to veterans for any any health care provider that: (1) was removed from VA employment for violating VA policy relating to the delivery of safe and appropriate health care, (2) violated medical license requirements, (3) had a VA credential revoked on grounds that impact the provider's ability to deliver safe and appropriate health care, or (4) violated a law for which a prison term of more than one year may be imposed. The VA may deny, revoke, or suspend a health care provider's eligibility to provide non-VA health care services based on a reasonable belief that such action is necessary to immediately protect the health or safety of veterans if: (1) the provider is under investigation by a state's medical licensing board, (2) the provider has entered into a settlement agreement for a disciplinary charge relating to the practice of medicine, or (3) the VA otherwise determines that such action is appropriate. The VA shall suspend a health care provider's eligibility to provide non-VA health care services to veterans if such provider is suspended from serving as a VA medical provider.
United States · United States Congress · 17 May 2017
Medicare Mental Health Inpatient Equity Act of 2017 This bill removes the 190-day lifetime limit on inpatient psychiatric hospital services under Medicare.
United States · United States Congress · 17 May 2017
Accelerating Innovation in Medicine Act of 2017 or the AIM Act of 2017 This bill requires the Centers for Medicare & Medicaid Services (CMS) to develop, maintain, and make publicly available a list of medical devices that shall be voluntarily excluded from payment under the Medicare program. A Medicare beneficiary who consents to receive such a medical device shall be responsible for payment for the device. A manufacturer seeking to have a medical device included in the list must submit a request for inclusion to the CMS, in accordance with specified timelines. As a condition for a device's continued inclusion on the list, a manufacturer must provide the CMS with data on clinical studies completed with respect to the device.
United States · United States Congress · 17 May 2017
Caring Recovery for Infants and Babies Act or the CRIB Act This bill amends title XIX (Medicaid) of the Social Security Act to allow a state Medicaid program to cover inpatient or outpatient services at a residential pediatric recovery center for infants with neonatal abstinence syndrome (a postnatal drug withdrawal syndrome) and their families.
United States · United States Congress · 17 May 2017
Quality Systems Certification Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish a third-party quality system assessment program to accredit persons to assess whether a medical device manufacturer's quality system can ensure the safety and effectiveness or substantial equivalence of an approved medical device after certain changes, including changes in manufacturing or changes to enhance device safety. Device manufacturers with quality systems that have been certified by an accredited person are allowed to make changes to a device without submitting to the FDA the premarket notification, 30-day notice, or premarket approval supplement that would otherwise be required. An accredited person who assesses a device manufacturer's quality system must submit a summary of their assessment and, as appropriate, a certification of the quality system to the FDA within 30 days of the assessment. An assessment summary and certification is deemed accepted by the FDA 30 days after submission unless the FDA determines that additional information is needed to support certification, the assessment or certification is unwarranted, or an action other than acceptance of the certification is otherwise justified. Device manufacturers who make changes to devices without submitting a premarket notification must describe the changes in an annual summary submitted to the FDA. Changes made without submitting a 30-day notice or a premarket approval supplement must be described in a periodic report. Certifications accepted by the FDA remain in effect for two years. The FDA must report on this quality system assessment program no later than January 31, 2022. The program is terminated at the end of FY2022.
United States · United States Congress · 17 May 2017
Expresses support for the goals and ideals of an International Day Against Homophobia and Transphobia. Encourages: (1) health care providers to offer culturally and clinically competent care to the lesbian, gay, bisexual, or transgender (LGBT) community; (2) schools to support the creation of gay-straight alliances to achieve safer learning environments; (3) individuals to learn about national resources for those who identify as LGBT; and (4) the federal government, states, international funding organizations, and U.S. bilateral and multilateral aid efforts to prioritize the health and human rights of LGBT people.
United States · United States Congress · 17 May 2017
Expanding Veterans' Access to Choice Act This bill amends the Veterans Access, Choice, and Accountability Act of 2014 to provide that a veteran who lives within 40 miles (calculated on distance traveled) of a Department of Veterans Affairs (VA) medical facility, including a community-based outpatient clinic, remains eligible to receive Veterans Choice program services through an approved private health care center if: (1) the VA cannot assign a full-time primary care physician to the veteran at any VA facility within such distance, or (2) no VA facility within such distance provides the needed hospital care or medical treatment.
United States · United States Congress · 17 May 2017
Medicaid Coverage for Addiction Recovery Expansion Act This bill amends title XIX (Medicaid) of the Social Security Act to allow states to provide medical assistance to adults for residential addiction treatment facility services under the Medicaid program if such services are offered as part of a full continuum of evidence-based treatment services. "Residential addiction treatment facility services" are medically necessary inpatient services provided in an accredited, size-limited facility for the purpose of treating a substance use disorder within a specified time period. The provision of medical assistance for such services to an individual shall not prohibit federal financial participation for medical assistance with respect to other services provided to the individual within the same time period. Subject to specified conditions, a woman who is eligible for medical assistance on the basis of being pregnant may remain eligible for residential addiction treatment facility services for specified time periods without regard to eligibility limits that would otherwise apply as a result of her pregnancy ending. In addition, the bill establishes a grant program for states to expand infrastructure and treatment capabilities of existing youth addiction treatment facilities that: (1) provide addiction treatment services to youths under Medicaid or the Children's Health Insurance Program (CHIP), and (2) are located in communities with high numbers of medically underserved populations of at-risk youths. At least 15% of grant funds awarded to a state must be used for making payments to rural facilities.
United States · United States Congress · 17 May 2017
Veterans' Health Care Integrity Act of 2017 This bill directs the Department of Veterans Affairs (VA) to ensure that the director of each VA medical facility annually certifies that: (1) the facility is in full compliance with all provisions of law and regulations relating to scheduling appointments for veterans hospital care and medical services, and (2) any official data on appointment wait times is accurate. The VA may not waive any applicable provision of such laws or regulations. If unable to make such certification, a director shall provide the VA with an explanation of any noncompliance and a description of compliance actions being taken. If a director does not make a certification for any year, each covered official may not receive specified awards or bonuses during the subsequent year. "Covered officials" are a facility's director, chief of staff, associate director, associate director for patient care, and deputy chief of staff. The VA shall ensure that its directives and policies apply to, and are implemented by, each VA office or facility in a uniform manner. The following VA positions shall be appointed by the President with the advice and consent of the Senate: (1) Deputy Under Secretary for Health for Operations and Management, (2) Deputy Under Secretary for Health for Policy and Services, (3) Principal Deputy Under Secretary for Benefits, (4) Deputy Under Secretary for Disability Assistance, and (5) Deputy Under Secretary for Field Operations.
United States · United States Congress · 17 May 2017
Medicaid Reform and Personal Responsibility Act of 2017 This bill requires state Medicaid programs to impose a work requirement upon enrollees who are able-bodied adults without dependents. Specifically, such enrollees must spend at least 20 hours per week working in a job, receiving on-the-job training, obtaining job skills, or doing community service. Such enrollees must also annually register with the state as employed or as unemployed and actively looking for employment.
United States · United States Congress · 17 May 2017
Caring Recovery for Infants and Babies Act or the CRIB Act This bill amends title XIX (Medicaid) of the Social Security Act to allow a state Medicaid program to cover inpatient or outpatient services at a residential pediatric recovery center for infants with neonatal abstinence syndrome (a postnatal drug withdrawal syndrome) and their families.
United States · United States Congress · 17 May 2017
Collaborative Academic Research Efforts for Tourette Syndrome Act of 2017 This bill amends the Public Health Service Act to require the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH research on Tourette syndrome. The NIH must: (1) develop a system to collect data on Tourette syndrome, including epidemiological information and data on the availability of medical and social services for individuals with Tourette syndrome and their families; (2) support Collaborative Research Centers for Tourette Syndrome to conduct basic and clinical research; (3) award grants for research on Tourette syndrome symptoms and treatment options for particular patient subpopulations; (4) designate funding to carry out Tourette syndrome programs and activities.
United States · United States Congress · 16 May 2017
Steve Gleason Enduring Voices Act of 2017 This bill amends title XVIII (Medicare) of the Social Security Act to make permanent the elimination of a specified payment cap under the Medicare program with respect to speech generating devices.
United States · United States Congress · 16 May 2017
FDA Reauthorization Act of 2017 Prescription Drug User Fee Amendments of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to extend through FY2022 and revise Food and Drug Administration (FDA) user fees for new drug applications. User fees are eliminated for supplements to new drug applications and drug manufacturing facilities. Medical Device User Fee Amendments of 2017 The bill extends through FY2022 and revises FDA user fees for medical devices. A user fee is established for requests to classify devices that are not substantially equivalent to marketed devices. The FDA is no longer granted the discretion to waive or reduce fees in the interest of public health. The FDA must establish a pilot program to accredit testing laboratories to determine whether medical devices conform to performance standards. The bill revises the types of medical devices that the FDA may accredit third parties to review. Generic Drug User Fee Amendments of 2017 The bill extends through FY2022 and revises FDA user fees for generic drugs. User fees are eliminated for supplements to generic drug applications. An annual fee is assessed on holders of approved generic drug applications. Biosimilar User Fee Amendments of 2017 The bill extends through FY2022 and revises FDA user fees for biosimilars. (Biosimilars are biological products approved by the FDA based on their similarity to an already-approved biological product.) User fees are eliminated for supplements to biosimilar applications and biosimilar manufacturing facilities. An annual fee is assessed on holders of approved applications for biosimilars. The bill sets the annual amount of revenue that must be generated by fees. The bill extends through FY2022 programs and policies including Critical Path Public-Private Partnerships, support for development of medical products for rare conditions, and the program to conduct pediatric studies of drugs.
United States · United States Congress · 16 May 2017
Puerto Rico Task Force Economic Empowerment Act of 2017 Puerto Rico Opportunity, Small Business Prosperity, and Economic Revitalization Act of 2017 This bill amends the Small Business Act to modify requirements for the microloan program for Puerto Rico small businesses and increase access to capital for such program. The Small Business Administration shall establish: (1) a Veteran Business Outreach Center in Puerto Rico, and (2) a temporary Federal and State Technology (FAST) grant program to provide assistance to Puerto Rico businesses. The bill amends the Investment Company Act of 1940 to apply the oversight requirements of that Act to investment companies in U.S. territories. The bill includes Puerto Rico in the Department of Labor reemployment demonstration projects grant program. For FY2018, Labor may transfer funding to the Bureau of Labor Statistics for feasibility studies of the Puerto Rico economy. The bill amends Social Security Act provisions affecting hospitals in Puerto Rico and health care and prescription drug coverage in U.S. territories. The Office of National Drug Control Policy shall develop a publicly available Caribbean Border Counternarcotics Strategy, with emphasis on the borders of Puerto Rico and the U.S. Virgin Islands.
United States · United States Congress · 16 May 2017
Medical Product Review Harmonization Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to establish an alternative standard for demonstrating a device's substantial equivalence to a medical device that has already been approved by the Food and Drug Administration.
United States · United States Congress · 16 May 2017
DMEPOS Access and Transparency Act of 2017 or the DATA Act of 2017 This bill directs the Centers for Medicare & Medicaid Services to implement prior-authorization processes under the Medicare program for certain medical equipment, prosthetics, orthotics, supplies, and services.
United States · United States Congress · 16 May 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017 This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products with a wholesale cost of $100 or more per month to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the cost of a drug over a 12-month period or a 25% or more increase over a 36-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1. Reports must contain specified information including pricing history and a justification for each price increase in the relevant period. Manufacturers that do not submit a required report are subject to a civil penalty. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency. HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.
United States · United States Congress · 16 May 2017
Commends the international community, health organizations, the private sector, school and community leaders, and faith-based organizations for bolstering health through vaccination. Recognizes that the lack of vaccination can cause a public health crisis and that there is no credible evidence that vaccines cause life-threatening or disabling diseases in healthy children or adults. Encourages a continued commitment to research to improve vaccines and develop new vaccines. Urges parents to follow the scientific evidence and consensus of medical experts in favor of timely vaccinations to protect their children and their community.
United States · United States Congress · 16 May 2017
Deborah Sampson Act This bill directs the Department of Veterans Affairs (VA) to carry out a three-year pilot program to assess the feasibility of peer-to-peer assistance for women veterans who are separating or newly separated from the Armed Forces), with emphasis placed on women who suffered service-related sexual trauma or who are at risk of becoming homeless. Additionally, the VA shall: expand the women veterans call center to include a text messaging capability; establish a partnership with at least one nongovernmental organization to provide legal services to women veterans based upon their 10 highest unmet needs; retrofit VA medical facilities with fixtures, materials, and other outfitting measures to support the care of women veterans; ensure that each VA medical facility has at least one full-time or part-time women's health primary care provider; expand to 14 days VA post-delivery care services for women veterans who are receiving maternity care in a VA or VA-contracted facility; ensure that the women veteran manager program is supported at each VA medical center with a program manager and an ombudsman; collect, analyze, and publish data on each VA service or benefit program and disaggregate such data by sex and minority status; and publish an Internet website that serves as a centralized information source for women veterans' benefits and services. The bill makes funds available for: (1) primary care and emergency care clinicians' participation in the women veterans health care mini-residency program, and (2) organizations that focus on providing assistance to women veterans and their families. The bill: (1) provides for reintegration and readjustment services to veterans and family members in group retreat settings, and (2) expresses the sense of Congress that the VA's motto should be more inclusive.
United States · United States Congress · 16 May 2017
Coast Guard Authorization Act of 2017 This bill authorizes: (1) appropriations for the Coast Guard for FY2018-FY2019, and (2) a specified level of end-of-year strength for active duty personnel and military training student loads for such fiscal years. The bill addresses: (1) training for public safety personnel, (2) service member benefits for Coast Guard personnel, (3) contracts to procure three National Security Cutters, and (4) the Coast Guard Reserve Officers' Training Corps Program. The bill revises or sets forth policies relating to the Coast Guard, including Coast Guard advisory committees, numbering for undocumented barges, aids to navigation, requirements for personal flotation devices, the alternate safety compliance program, vessel certification, the installation and use of engine cut-off switches on recreational vessels, visual distress signals for recreational boats, auxiliary craft requirements, the Coast Guard's inland waterway and river tenders fleet, arctic planning, maritime security, acquisition workforce expedited hiring authority, drawbridges, incentive contracts for Coast Guard Yard or Coast Guard industrial establishments, Coast Guard health care professionals, land exchanges, shipyards, and waivers for certain contracts.
United States · United States Congress · 16 May 2017
Patient Access to Higher Quality Health Care Act of 2017 This bill amends the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 to repeal specified limitations, for purposes of Medicare participation, on self-referrals by newly constructed or expanded physician-owned hospitals.
United States · United States Congress · 16 May 2017
Steve Gleason Act of 2017 This bill amends title XVIII (Medicare) of the Social Security Act to make permanent the elimination of a specified payment cap under the Medicare program with respect to speech generating devices.
United States · United States Congress · 16 May 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017 This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products with a wholesale cost of $100 or more per month to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the cost of a drug over a 12-month period or a 25% or more increase over a 36-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1. Reports must contain specified information including pricing history and a justification for each price increase in the relevant period. Manufacturers that do not submit a required report are subject to a civil penalty. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency. HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.
United States · United States Congress · 16 May 2017
Rural Emergency Acute Care Hospital Act This bill revises provisions related to health care in rural areas, including by allowing certain small rural hospitals and critical access hospitals to be designated as rural emergency hospitals for purposes of receiving special payment under Medicare.
United States · United States Congress · 16 May 2017
Expresses support for the goals and ideals of National Nurses Week. Recognizes the contributions of nurses to the U.S. health care system.
United States · United States Congress · 15 May 2017
Action for Dental Health Act 2017 This bill amends the Public Health Service Act to reauthorize oral health promotion and disease prevention programs through FY2022. The Centers for Disease Control and Prevention (CDC) may award grants or enter into contracts to obtain portable or mobile dental equipment and pay operational costs for the provision of free dental services to underserved populations. The CDC may also award grants or enter into contracts to collaborate with state, county, or local public officials and other stakeholders to develop and implement initiatives to: (1) improve oral health education and dental disease prevention; (2) make the dental services delivery system more accessible and efficient through outreach programs that facilitate the establishment of dental homes; (3) reduce geographic barriers, language barriers, cultural barriers, and other similar barriers in the provision of dental services; (4) reduce the use of emergency departments by individuals who seek dental services more appropriately delivered in a dental primary care setting; or (5) facilitate the provision of dental care to nursing home residents who are disproportionately affected by lack of care.
United States · United States Congress · 15 May 2017
Office of National Drug Control Policy Reauthorization Act of 2017 This bill reauthorizes the Office of National Drug Control Policy through FY2023. It amends the definition of "demand reduction" in a National Drug Control Program to include screenings, interventions, promoting availability of and access to health care services, and support for long-term recovery from substance abuse disorders. It defines "illicit drug use," "illegal drug use," and like terms to include the illegal use of prescription drugs. The Director of the National Drug Control Policy (Director) shall be directly responsible for demand reduction activities, supply reduction activities, and for state, local, and tribal affairs. The Director shall require each National Drug Control Program agency to submit to the Director on an annual basis an evaluation of progress by the agency regarding implementation of drug recovery programs. The Director shall also ensure that drug recovery research is effectively disseminated by the National Drug Control Program agencies to state and local governments and nongovernmental agencies involved in demand reduction. The President shall submit to Congress a National Drug Control Strategy, which shall set forth a comprehensive plan for the year to reduce illicit drug use and the consequences of such use by promoting prevention, early intervention, treatment, and recovery support for individuals with substance abuse disorders. The Director shall submit to Congress a report evaluating high intensity drug trafficking areas (HIDTAs) as part of the National Drug Control Strategy, assessing drug enforcement task forces in HIDTAs, and assessing law enforcement intelligence sharing in HIDTAs.
United States · United States Congress · 11 May 2017
Maternal Health Accountability Act of 2017 This bill directs the Department of Health and Human Services (HHS) to establish a program under which HHS may make grants to states (including federally recognized Indian tribes and organizations) for the purpose of: (1) reviewing pregnancy-related and pregnancy-associated deaths (maternal deaths); (2) establishing and sustaining a maternal mortality review committee to review relevant information; (3) ensuring that the state department of health develops a plan for ongoing health care provider education in order to improve the quality of maternal care, disseminate findings, and implement recommendations; (4) disseminating a case abstraction form to aid information collection for HHS review and preserve its uniformity; and (5) providing for the public disclosure of information included in state reports. The bill defines "pregnancy-associated death" as the death of a woman while pregnant or during the one-year period following the date of the end of pregnancy, irrespective of the cause of death. It defines "pregnancy-related death" as the death of a woman while pregnant or during the one-year period following the date of the end of pregnancy, irrespective of the pregnancy's duration, from any cause related to, or aggravated by, the pregnancy or its management, excluding any accidental or incidental cause. States shall develop procedures for mandatory reporting to their departments of health by health facilities and professionals concerning maternal deaths and for voluntary reporting of such deaths by family members. States shall investigate each case and prepare a case summary for each case, to be reviewed by the committee and included in applicable reports. The bill amends the Public Health Service Act to direct HHS to take specified steps to eliminate disparities in maternal health outcomes.
United States · United States Congress · 11 May 2017
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 This bill amends the Public Health Service Act to authorize the Department of Health and Human Services to make grants to states to: (1) collect data on the prevalence and distribution of sickle cell disease, (2) conduct sickle cell disease public health initiatives to improve access to care and health outcomes, and (3) identify and evaluate strategies for prevention and treatment of sickle cell disease complications. The demonstration program to improve the prevention and treatment of sickle cell disease is revised, reauthorized through FY2022, and moved from the American Jobs Creation Act of 2004 to the Public Health Service Act.
United States · United States Congress · 11 May 2017
Menstrual Products Right to Know Act of 2017 This bill requires menstrual products, such as menstrual cups, menstrual pads, tampons, and therapeutic vaginal douche apparatuses, to include a list of ingredients on the label.
United States · United States Congress · 11 May 2017
Supports the designation of Mental Health Month to remove the stigma associated with mental illness and to place emphasis on scientific findings regarding mental health recovery.
United States · United States Congress · 11 May 2017
This bill directs the Department of Veterans Affairs (VA) to ensure that payments made to non-VA health care providers, including payments under the Veterans Choice Program, comply with the Prompt Payment Act and the requirements set forth in this bill. The bill: (1) prescribes payment schedules; (2) requires, with exceptions, claims to be submitted electroncially beginning January 1, 2019; and (3) requires the VA Chief Information Officer to establish by such date an electronic interface for health care providers to submit reimbursement claims. The VA shall: (1) within 90 days after enactment of this bill, make necessary modifications to ensure prompt payment for hospital care or medical treatment furnished under the program, and (2) within 180 days after enactment of this bill, adjudicate all program claims submitted before such date by non-VA health care providers.
United States · United States Congress · 11 May 2017
Making Pharmaceutical Markets More Competitive Act This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to prioritize the review of generic drug applications and supplements with respect to drugs that are in a shortage or for which there are not more than three approved drugs. The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale. The FDA must maintain a list of generic drugs with three or fewer holders of approved applications.
United States · United States Congress · 11 May 2017
Personal Care Products Safety Act This bill amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. Companies must pay a facility registration fee based on their annual gross sales of cosmetics. The collected fees can only be used for cosmetic safety activities. If the FDA determines that a cosmetic has a reasonable probability of causing serious adverse health consequences, it may prohibit the cosmetic's distribution by suspending the cosmetic ingredient statement. If other cosmetics from the same facility may be affected, the FDA may prohibit distribution from the facility by suspending the facility's registration. The FDA must review the safety of at least five cosmetic ingredients each year, and it may establish conditions for safe use of an ingredient, including a limit on the amount of the ingredient or a requirement for a warning label. A cosmetic cannot be sold if it contains an ingredient that is not safe, not safe under the recommended conditions of use, or not safe in the amount present in the cosmetic. Cosmetics companies are required to report to the FDA any serious adverse health event associated with their cosmetics. The FDA must: develop and implement cosmetic manufacturing standards that are consistent with existing national and international standards, be allowed to inspect a company's cosmetic safety records, recall a cosmetic that is likely to cause serious adverse health consequences, and encourage cosmetic safety testing practices that minimize the use of animals.
United States · United States Congress · 11 May 2017
Violence Against Women Veterans Act This bill requires the Department of Veterans Affairs (VA) to carry out a program to assist veterans that have experienced or are experiencing domestic violence or sexual assault in accessing benefits from the VA, including by coordinating access to medical treatment centers, housing assistance, and other benefits. The VA shall carry out the program in partnership with specified health care or other service providers that serve domestic violence or sexual assault victims. The VA may: (1) conduct training for community-based domestic violence or sexual assault service providers on identifying veterans who have been victims, coordinating with local VA service providers, and connecting veterans with appropriate VA housing, mental health, medical, and other financial assistance or benefits; and (2) provide assistance to service providers to ensure veterans access to domestic violence and sexual assault emergency services. The VA may establish local coordinators to provide outreach under such program and ensure that each coordinator is knowledgeable about: the dynamics of domestic violence and sexual assault, including safety concerns, legal protections, and the need for confidential services; veteran eligibility for VA services and benefits relevant to recovery from domestic violence and sexual assault; and local community resources addressing domestic violence and sexual assault. Each coordinator shall assist domestic violence shelters and rape crisis centers in providing services to veterans. The VA shall: (1) establish a national task force to develop a comprehensive national program to address domestic violence and sexual assault among veterans, and (2) conduct a national baseline study to examine the scope of the problem of domestic violence and sexual assault among veterans and spouses of veterans.
United States · United States Congress · 11 May 2017
Title VIII Nursing Workforce Reauthorization Act of 2017 This bill amends the Public Health Service Act to extend through FY2022 support for nursing workforce programs and grants. Eligibility for advanced nursing education grants is expanded to include education programs for clinical nurse leaders and all combined registered nurse and graduate degree programs. (Clinical nurse leaders are advanced generalist clinicians who apply research and coordinate care in order to improve outcomes for patients.) To be eligible for these grants, clinical nurse specialist programs must provide registered nurses with full-time clinical nurse specialist education that qualifies the nurses to provide a full range of care. Programs for loan repayment and scholarships for nurses, loans for nursing faculty, and geriatric care education are extended through FY2022. Grants for increasing nursing workforce diversity are also extended through FY2022. Nurse education, practice, and quality grants are extended through FY2022 and eligibility is expanded to include nurse-managed health clinics. Grants for nursing career ladder programs are expanded to: (1) promote career advancement for individuals to become registered nurses or advanced education nurses; and (2) support internships and residency programs to encourage mentoring and the development of specialties.
United States · United States Congress · 11 May 2017
National Nurse Act of 2017 This bill amends the Public Health Service Act to require the Department of Health and Human Services to designate the Chief Nurse Officer of the Public Health Service as the National Nurse for Public Health. The duties of this position include: (1) providing leadership and coordination of Public Health Service nursing professional affairs for the Office of the Surgeon General and other agencies of the Public Health Service, (2) conducting outreach and education, and (3) providing guidance and leadership for activities that will increase public safety and emergency preparedness. The National Nurse for Public Health must: (1) participate in identification of national health priorities, (2) encourage volunteerism of nurses and strengthen the relationship between government agencies and health-related national organizations, and (3) promote the dissemination of evidence-based practice in educating the public on health promotion and disease prevention activities.
United States · United States Congress · 10 May 2017
Pediatric Device Development Act This bill revises requirements for the Food and Drug Administration regarding (1) the annual report on the pediatric use of medical devices, and (2) application procedures for pediatric medical devices. The bill also extends the authorizations for (1) the humanitarian device exemption, and (2) demonstration grants for improving pediatric device availability.
United States · United States Congress · 9 May 2017
Protecting Americans from Dangerous Opioids Act This bill requires the Food and Drug Administration (FDA) to revoke approval for an opioid drug for every new opioid drug approved. (Opioids are drugs with effects similar to opium, such as certain pain medications.) In determining the drug for which to revoke approval, the FDA must prioritize revoking approval for drugs that are not abuse deterrent and consider the public health impact of drugs on the market.
United States · United States Congress · 9 May 2017
FDA Accountability for Public Safety Act This bill amends the Comprehensive Addiction and Recovery Act of 2016 to expand the scope of the Food and Drug Administration (FDA) advisory committee to make recommendations regarding supplemental applications for opioids. Currently, the committee only makes recommendations on new drug applications. Only the Commissioner of Food and Drugs may approve a new drug application or supplement to an application for an opioid against the recommendation of the committee. If the Commissioner approves a drug against the recommendation of the committee, the Commissioner must: (1) submit a report to Congress that includes the evidence regarding patient safety that supports the Commissioner's decision and a disclosure of any potential conflicts of interest of FDA officials involved in the decision; and (2) testify before Congress regarding the decision, upon request. Such a drug cannot be sold until the Commissioner has submitted the report.